TQB2101 not checked
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TQB2101 for Injection is an ROR1 ADC, an antibody-drug conjugate. It consists of three main components: a ROR1 monoclonal antibody responsible for selectively recognizing the surface antigen of cancer cells, a small molecule toxin responsible for killing cancer cells, and a linker connecting the antibody and the small molecule toxin. It is intended for clinical use in the treatment of advanced…”In the company’s words, NCT07113925 on ClinicalTrials.gov
- Main trialPhase 1
- “TQB2101 for Injection is an Antibody-Drug Conjugate (ADC) targeting Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1).It consists of three main components: a ROR1 monoclonal antibody responsible for selectively recognizing the surface antigen of cancer cells, a small molecule toxin responsible for killing cancer cells, and a linker connecting the antibody and the small molecule toxin. It is intended for clinical use in the treatment of advanced malignant tumors, including advanced malignant hematological tumors.”In the company’s words, NCT07113925 on ClinicalTrials.gov
Other drugs for Advanced Hematologic Malignancies
- Givinostat HydrochlorideItalfarmaco · Phase 3
- QTX-2101Quetzal Therapeutics · Phase 3
- RusfertideProtagonist Therapeutics, Inc. · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- Human immunoglobulin GCSL Behring · Phase 3
- PelabresibNovartis · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Dec 2025 | A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies | |
| Phase 1Not yet recruiting | Oct 2026 | To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026